Genesis Therapeutics develops an AI platform called GEMS (Genesis Exploration of Molecular Space) to generate and optimize small-molecule drug candidates. The platform integrates proprietary AI methods, including language models, diffusion models, and physical machine‑learning simulations, to handle complex targets. The company is led by Founder and CEO Evan Feinberg, Ph.D., and is collaborating with NVIDIA to accelerate and make GEMS computation more efficient. Planned technical work with NVIDIA includes optimizing equivariant neural networks for 3D geometric data such as protein and small-molecule structures. Financially, Genesis announced an equity investment from NVIDIA’s NVentures (amount undisclosed) and previously completed a $200M Series B in August 2023 in which NVentures participated. The new funds are intended to accelerate development and deployment of the GEMS platform. Genesis Therapeutics develops small-molecule drug candidates using a proprietary generative and predictive AI platform called GEMS, which integrates deep learning, molecular simulations, and chemically aware language models. The platform is used to generate novel molecules and rapidly predict properties such as potency, selectivity, and ADMET to accelerate candidate selection and iterative optimization. Genesis has built an internal discovery pipeline with multiple programs targeting data-poor and canonically undruggable targets. The company intends to use new capital to advance its wholly owned AI-enabled programs into clinical development and to expand its pipeline toward underserved patient populations. Genesis also plans continued investment in state-of-the-art generative and predictive AI methods to further develop the GEMS platform. The company is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego and has announced collaborations with Genentech and Eli Lilly. Genesis Therapeutics develops an AI platform that represents molecules as rich 3D graphs and combines modern deep neural networks with biophysical simulation to predict binding affinity, solubility and other properties. The company’s Dynamic PotentialNet approach models multiple contact types, spatial distances and conformational changes of ligands and proteins. Genesis has pursued partnerships (including one with Genentech) while also building an internal development process to find and advance drug candidates. Founder Evan Feinberg built the team and platform around improved molecular representation and simulation, informed by chemists with drug-development experience. The company plans to expand its headcount across AI research, software engineering, medicinal chemistry and biotech roles and to build its own research labs funded by the recent financing. Genesis views advances in protein-structure prediction (e.g., AlphaFold) as complementary tailwinds for its platform. Genesis Therapeutics develops a proprietary molecular AI platform to accelerate and optimize discovery and development of small-molecule therapeutics. Its technology originated with PotentialNet from the Pande Lab at Stanford and was validated in collaboration with Merck Research Laboratories. The company was founded in 2019 by Evan Feinberg and Ben Sklaroff and is based in South San Francisco. Genesis aims to discover and internally develop novel small-molecule drug candidates for severe and debilitating disorders and to strategically partner with pharmaceutical companies to bring select candidates to market. With $4.1M in seed funding led by Andreessen Horowitz and participation from Felicis Ventures, the company is expanding its AI-enabled drug discovery team and actively recruiting software, AI engineers, and scientists. Leadership and advisers include experienced industry figures such as Leonard Bell (Board Chair) and Peppi Prasit (Scientific Advisory Board), and the firm emphasizes continued innovation in deep learning and biophysical simulation.

Total raised

$256M

Funding rounds

4

Latest round

Series B

Latest activity

Aug 2023